PDS Biotechnology Announces $6 Million Debt Financing and New ATM Offering Agreement

On April 30, 2026, PDS Biotechnology Corporation entered into a Securities Purchase Agreement with YA II PN, LTD. (the Investor) for the issuance and sale of a $6.0 million promissory note and a warrant to purchase up to 2,158,274 shares of common stock at an exercise price of $1.1824 per share. The promissory note, issued at a purchase price of $5.76 million, carries a 10% annual interest rate and matures in twelve months. The transaction is expected to close around June 12, 2026. Simultaneously, the company entered into a new 'at-the-market' sales agreement with Yorkville Securities, LLC and terminated its previous sales agreement with B. Riley Securities and H.C. Wainwright & Co. PDS Biotechnology also issued a redemption notice to prepay all outstanding principal under its existing Senior Secured Convertible Debentures, effectively refinancing its debt. Proceeds from the new sales agreement will be partially used to satisfy amortization payments on the new promissory note.